TauRx Pharmaceuticals Ltd. is a clinical-stage biotechnology company headquartered in Aberdeen, Scotland, focused exclusively on developing tau-based therapies for Alzheimer's disease and other neurodegenerative disorders. The company is a pioneer in tau aggregation inhibitor (TAI) research, with over two decades of experience targeting the tau protein pathology that correlates strongly with cognitive decline in Alzheimer's disease["@taurx"].
Founded in 2002 as a spinout from the University of Aberdeen, TauRx has advanced the most advanced oral tau aggregation inhibitor in clinical development. The company's flagship compound, hydromethylthionine mesylate (HMTM), has demonstrated significant cognitive benefits in Phase 3 clinical trials["@hmtm2023"].
HMTM is a [tau aggregation inhibitor](/therapeutics/tau-aggregation-inhibitors) that works through a unique dual mechanism:
Direct tau aggregation inhibition: Binds to [tau protein](/proteins/tau) aggregates and prevents their growth and spread
Pseudo-aggregation inhibition: Acts as a "pseudo-substrate" that blocks the template-driven aggregation of pathological tau
Key Properties:
Brain-penetrant small molecule
Oral administration
Good safety and tolerability profile
No ARIA ([Amyloid-Related Imaging Abnormalities](/diagnostics/aria-monitoring)) risk
Long-term treatment sustainability
Clinical Development
Phase 3 Results (TRx-237-007):
The pivotal Phase 3 study in approximately 500 patients with mild-to-moderate [Alzheimer's disease](/diseases/alzheimers-disease) demonstrated:
Significant reduction in cognitive decline on [ADAS-Cog](/diagnostics/adas-cog)
Reduced [brain atrophy](/mechanisms/brain-atrophy) rate on [MRI](/technologies/mri-neuroimaging)
Benefits seen within 6 months of treatment
Good tolerability with no ARIA
Regulatory Status:
Approved in the United Kingdom (2023) for treating Alzheimer's disease
Under review in other territories
Tau Pathology and Alzheimer's Disease
Why Target Tau?
While [amyloid-beta](/mechanisms/amyloid-beta-aggregation) has been the primary focus of Alzheimer's research, [tau pathology](/mechanisms/tau-pathology) correlates more strongly with cognitive decline:
Neurofibrillary tangles: Made of aggregated [tau protein](/proteins/tau)
Spread pattern: Follows a predictable pattern correlating with cognitive impairment
Mechanism: Toxic tau species propagate across brain regions
Therapeutic window: Tau aggregation can be inhibited pharmacologically
Tau Aggregation Process
The formation of toxic tau aggregates involves:
[Hyperphosphorylation of tau](/mechanisms/tau-hyperphosphorylation)
Conformational change
Oligomerization
Fibril formation
Neurofibrillary tangles
[Neuronal dysfunction and death](/mechanisms/neuronal-death)
| Name | Position | Background | |------|----------|------------| | [Dr. Claude Wischik](/researchers/claude-wischik) | CEO & Co-founder | Tau biology researcher | | [Prof. Peter St George-Hyslop](/researchers/peter-st-george-hyslop) | SAB Chair | Neuroscience researcher | | Dr. Michael Wittenberg | CMO | Clinical development |